The effect of umeclidinium added to inhaled corticosteroid/long-acting β(2)-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study

Benefits of triple therapy with a long-acting muscarinic antagonist (LAMA), added to inhaled corticosteroid (ICS)/long-acting β(2)-agonist (LABA), have been demonstrated. Limited data assessing the efficacy of the LAMA umeclidinium (UMEC) added to ICS/LABA are available. The aim of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa, Ana R, Riley, John H, Church, Alison, Zhu, Chang-Qing, Punekar, Yogesh S, Fahy, William A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918053/
https://www.ncbi.nlm.nih.gov/pubmed/27334739
http://dx.doi.org/10.1038/npjpcrm.2016.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918053/
https://www.ncbi.nlm.nih.gov/pubmed/27334739
http://dx.doi.org/10.1038/npjpcrm.2016.31

Ejemplares similares